“In terms of efficacy, the results of phase 2 and 3 clinical trials show that Paxlovid can reduce the risk of hospitalization or death by 89% in adult Covid-19 patients who are not hospitalized with comorbidities, such as the elderly, the obese, active smoker, people with history of heart disease, diabetes, or kidney problem,” explained Penny.
She also appreciated the contribution and support from various parties, namely the expert team of the National Committee for Drug Evaluation and the association of clinicians who had studied the drug intensively until the EUA was approved. Furthermore, BPOM alongside the Health Ministry will continue to monitor the safety of Paxlovid in Indonesia.
Read: Rosella extract stops liver fat formation
“We urge the public to be more vigilant before buying or consuming medicine. People must be smart consumers and avoid taking illegal drugs. Make sure to only buy drugs that already have a distribution permit. Buy drugs at official facilities, namely pharmacies, drug stores, health centers or the nearest hospital or online at pharmacies that already have a Pharmacy Electronic System Operator (PSEF) permit. To get hard drugs, of course, they still have to be based on a doctor’s prescription,” said Penny.
Paxlovid is a SARS-CoV-2 protease inhibitor antiviral therapy developed and manufactured by Pfizer. Previously, BPOM had issued EUA for Favipiravir and Remdesivir in 2020, monoclonal antibodies Regdanvimab in 2021, and Molnupiravir in 2022. (rr)